OBJECTIVES: To describe the proportion of patients receiving drugs with a narrow therapeutic range who lacked serum drug concentration monitoring during a 1-year period of therapy and to identify patient characteristics associated with lack of monitoring. STUDY DESIGN: Retrospective cohort. METHODS: Ambulatory patients (n = 17,748) at 10 health maintenance organizations who were receiving ongoing continuous drug therapy with digoxin, carbamazepine, divalproex sodium, lithium carbonate, lithium citrate, phenobarbital sodium, phenytoin, phenytoin sodium, primidone, quinidine gluconate, quinidine sulfate, procainamide hydrochloride, theophylline, theophylline sodium glycinate, tacrolimus, or cyclosporine for at least 12 months between January 1, 1999, and June 30, 2001, were identified. Serum drug concentration monitoring was assessed from administrative data and from medical record data. RESULTS: Fifty percent or more of patients receiving digoxin, theophylline, procainamide, quinidine, or primidone were not monitored, and 25% to 50% of patients receiving divalproex, carbamazepine, phenobarbital, phenytoin, or tacrolimus were not monitored. Younger age was associated with lack of monitoring for patients prescribed digoxin (adjusted odds ratio, 1.86; 95% confidence interval, 1.39-2.48) and theophylline (adjusted odds ratio, 1.58; 95% confidence interval, 1.23-2.04), while older age was associated with lack of monitoring for patients prescribed carbamazepine (adjusted odds ratio, 0.59; 95% confidence interval, 0.44-0.80) and divalproex (adjusted odds ratio, 0.50; 95% confidence interval, 0.38-0.66). Patients with fewer outpatient visits were also less likely to be monitored (P < .001). CONCLUSIONS: A substantial proportion of ambulatory patients receiving drugs with narrow intervals between doses resulting in beneficial and adverse effects did not have serum drug concentration monitoring during 1 year of use. Clinical implications of this finding need to be evaluated.
OBJECTIVES: To describe the proportion of patients receiving drugs with a narrow therapeutic range who lacked serum drug concentration monitoring during a 1-year period of therapy and to identify patient characteristics associated with lack of monitoring. STUDY DESIGN: Retrospective cohort. METHODS: Ambulatory patients (n = 17,748) at 10 health maintenance organizations who were receiving ongoing continuous drug therapy with digoxin, carbamazepine, divalproex sodium, lithium carbonate, lithium citrate, phenobarbital sodium, phenytoin, phenytoin sodium, primidone, quinidine gluconate, quinidine sulfate, procainamide hydrochloride, theophylline, theophylline sodium glycinate, tacrolimus, or cyclosporine for at least 12 months between January 1, 1999, and June 30, 2001, were identified. Serum drug concentration monitoring was assessed from administrative data and from medical record data. RESULTS: Fifty percent or more of patients receiving digoxin, theophylline, procainamide, quinidine, or primidone were not monitored, and 25% to 50% of patients receiving divalproex, carbamazepine, phenobarbital, phenytoin, or tacrolimus were not monitored. Younger age was associated with lack of monitoring for patients prescribed digoxin (adjusted odds ratio, 1.86; 95% confidence interval, 1.39-2.48) and theophylline (adjusted odds ratio, 1.58; 95% confidence interval, 1.23-2.04), while older age was associated with lack of monitoring for patients prescribed carbamazepine (adjusted odds ratio, 0.59; 95% confidence interval, 0.44-0.80) and divalproex (adjusted odds ratio, 0.50; 95% confidence interval, 0.38-0.66). Patients with fewer outpatient visits were also less likely to be monitored (P < .001). CONCLUSIONS: A substantial proportion of ambulatory patients receiving drugs with narrow intervals between doses resulting in beneficial and adverse effects did not have serum drug concentration monitoring during 1 year of use. Clinical implications of this finding need to be evaluated.
Authors: Steven M Handler; Joseph T Hanlon; Subashan Perera; Melissa I Saul; Douglas B Fridsma; Shyam Visweswaran; Stephanie A Studenski; Yazan F Roumani; Nicholas G Castle; David A Nace; Michael J Becich Journal: AMIA Annu Symp Proc Date: 2008-11-06
Authors: Zachary A Marcum; Megan E Amuan; Joseph T Hanlon; Sherrie L Aspinall; Steven M Handler; Christine M Ruby; Mary Jo V Pugh Journal: J Am Geriatr Soc Date: 2011-12-08 Impact factor: 5.562
Authors: Marsha A Raebel; LeeAnn M Quintana; Emily B Schroeder; Susan M Shetterly; Lisa E Pieper; Paul L Epner; Laura K Bechtel; David H Smith; Andrew T Sterrett; Joseph A Chorny; Ira M Lubin Journal: Arch Pathol Lab Med Date: 2018-12-10 Impact factor: 5.534
Authors: Shira H Fischer; Terry S Field; Shawn J Gagne; Kathleen M Mazor; Peggy Preusse; George Reed; Daniel Peterson; Jerry H Gurwitz; Jennifer Tjia Journal: J Gen Intern Med Date: 2012-11-15 Impact factor: 5.128
Authors: Steven M Handler; Joseph T Hanlon; Subashan Perera; Yazan F Roumani; David A Nace; Douglas B Fridsma; Melissa I Saul; Nicholas G Castle; Stephanie A Studenski Journal: J Am Geriatr Soc Date: 2008-03-21 Impact factor: 5.562
Authors: Jaclyn M LeBlanc; Kayla Cameron-Coffill; Jodi L Symes; Sandra Kane-Gill; Kevin Duplisea; John Mowatt Journal: Can J Hosp Pharm Date: 2017-02-28
Authors: Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede Journal: J Antimicrob Chemother Date: 2019-10-01 Impact factor: 5.790
Authors: Willemijn L Eppenga; Cornelis Kramers; Hieronymus J Derijks; Michel Wensing; Jack F M Wetzels; Peter A G M De Smet Journal: Eur J Clin Pharmacol Date: 2016-08-27 Impact factor: 2.953